By: Francis S. Mah, MD; Marguerite McDonald, MD, FACS; George O. Waring IV, MD, FACS
This course has expired. You can still review the content but course credit is no longer available.
Pharmaceutical options for treatment of presbyopia will change the conversations between eye care providers and patients. These drugs will also act as a gateway for many more patients to visit optometrists and ophthalmologists—in particular presbyopic emmetropes. The current options simply do not completely satisfy all patients.
This webinar includes engaging discussions among the panel members related to underlying mechanisms of presbyopic changes; pharmacological properties of newly emerging presbyopia correcting drops and their mechanisms of action; and how presbyopia-correcting drops are likely to affect categories of patients based on individual characteristics.
Supported by an unrestricted medical education grant from AbbVie.
Upon completion of this activity, the participant should be able to:
This educational activity is provided by Evolve Medical Education LLC (Evolve).
Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement[s] for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting credit.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Francis S. Mah, MD
Director of Corneal and External Disease
Co-Director of Refractive Surgery
Scripps Clinic
La Jolla, CA
Marguerite McDonald, MD, FACS
Clinical Professor of Ophthalmology
NYU Langone Medical Center
New York, New York
Clinical Professor of Ophthalmology
Tulane University Health Sciences Center
New Orleans, Louisiana
OCLI Vision
Oceanside, NY
George O. Waring IV, MD, FACS
Founder and Medical Director
Waring Vision Institute
Mount Pleasant, SC
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Francis S. Mah, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Bausch + Lomb, Eyenovia, Glaukos, iView, Johnson & Johnson Vision, Nevakar, Novartis, Ocular Science, and RxSight.
Marguerite McDonald, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon Vision, Allergan, Bausch + Lomb, Blephex, Johnson & Johnson Vision, NTK Enterprises, Orca Surgical, Ocusoft, Oculus USA, Quidel, Stroma, Sun Pharma Industries, TearLab, Tissue Tech, and VISUS. Stock/Shareholder: Ocuphire and RxSight.
George O. Waring IV, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan and Johnson & Johnson.
The Evolve staff and planners have no financial relationships with commercial interests.
Mark Goerlitz-Jessen, MD, peer reviewer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or AbbVie.